[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Toulouse\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":687},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,179,0,25,[9,43,73,98,122,153,176,205,231,261,285,312,337,365,390,417,446,469,491,523,550,573,603,626,654],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100517220","modelling-of-pharyngeal-laryngeal-effectiveness-100517220",false,"NCT06014710","Modelling of Pharyngeal Laryngeal Effectiveness","Modelling of Pharyngeal Laryngeal Effectiveness to Assess Swallowing Disorders","Eph-L","Inclusion criteria for patients with swallowing disorders :\n\n* Indication to perform a swallowing test (suspected or proven swallowing disorder or presence of a complication)\n* Able to follow up by phone for 6 months or have a caregiver who can answer for them\n* Affiliated subject or beneficiary of the social security system\n* Consent to participate obtained in writing and signed by the subject or, if applicable, the next of kin\u002Fsupport person\n\nInclusion criteria for healthy volunteers :\n\n* No swallowing disorder or discomfort (DHI score\\\u003C8)\n* Affiliated subject or beneficiary of the social security system\n* Signed Consent to Participate\n\nNon-inclusion criteria for patients with swallowing disorders :\n\n* Skin lesion(s) at the neck\n* Tracheotomy or tracheostomy (laryngectomy)\n* Nasogastric probe\n* Iodine allergy\n* Asthma\n* Refusal or any pathology incompatible with passing one of the two reference exams or the sensors used\n* Any serious pathology (severe health or behavioral disorders) where, according to the investigator, this could expose participants to additional risks\n* Legal protection (guardianship, curators, safeguarding of justice)\n* Pregnant and lactating women\n\nNon-inclusion criteria for healthy volunteers :\n\n* Medical history may result in chronic (history of oral-rhino-laryngeal cancer or neurological disease) or temporary (upper respiratory tract infections) swallowing impairment\n* Presence of swallowing disorder or discomfort (Deglutition Handicap Index score superior or equal to 8)\n* Skin lesion(s) at the neck\n* Tracheotomy or tracheostomy (laryngectomy)\n* Nasogastric probe\n* Iodine allergy\n* Asthma\n* Refusal or any pathology incompatible with passing one of the two reference exams or the sensors used\n* Any serious pathology (severe health or behavioral disorders) where, according to the investigator, this could expose participants to additional risks\n* Legal protection (guardianship, curators, safeguarding of justice)\n* Pregnant and lactating women",true,"ALL","18 Years",{"count":22,"type":23},520,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this study is to collect the signals of pharyngeal laryngeal activity through five non-invasive sensors (microphone, accelerometer, surface electromyography (EMG), nasal cannula and oximeter) in order to identify indicators of functional efficiency of swallowing, protection of the lower airways and phonation.\n\n440 patients (subjects with swallowing disorders), spread over 4 centers and 80 healthy subjects spread over 2 centers will be recruited for the study in an interventional research study involving the prospective, multicentric and longitudinal.\n\nPharyngolaryngeal effectiveness will be measured from 6 indicators identified by examinations or reference tests grouped into 3 functions:\n\n* swallowing: pharyngeal transport capacity (Yale Residue) and Penetration Aspiration Scale (PAS) rated by videofluoroscopy of swallowing (VFS) or flexible endoscopic evaluation of swallowing (FEES);\n* airway protection: cough trigger (citric acid test) and cough power (peak expiratory flow);\n* phonation: vocal efficiency (maximum phonation time) and velar efficiency (nasal scores).\n\nThe signals obtained from the 5 sensors will be annotated. Stochastic modelling based on hidden Markov models will be used initially and followed by the implementation of deep neural networks to model indicators. For the complication's prediction algorithm, deep neural networks will also be used to evaluate signal-based methods.\n\nThe expected benefits are to obtain automated recognition of pharyngeal-laryngeal effectiveness to diagnose swallowing disorders using objective and quantifiable indicators, non-invasive devices, to assess the severity of these disorders and to identify the risk of complications.",[29],"Swallowing Disorders","RECRUITING","2026-08-11",{"date":33,"type":34},"2026-08-13","ACTUAL",{"date":36,"type":34},"2023-04-14",{"date":38,"type":23},"2027-10",{"name":40,"class":41},"University Hospital, Toulouse","OTHER",4,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":18,"sex":19,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100651904","development-and-validation-of-a-scale-of-propensity-for-change-in-chronic-disease-prevention-100651904","NCT07765797","Development and Validation of a Scale of Propensity for Change in Chronic Disease Prevention","Development and Validation of a Propensity-to-change Scale in the Field of Chronic Disease Prevention: the ProChange Scale","ProChange","Inclusion Criteria:\n\n* Participant receiving a personalized prevention intervention through the frailty assessment day-hospital program, the Atherosclerosis Detection and Prevention Center (CDPA), or the Salutance program,\n* Participant who has received prevention advice aimed at improving their health in at least one of the following two areas: nutrition or physical activity,\n* Participant aged 45 or older (we are targeting a middle-aged to older population, as this group is the primary target for cardiovascular prevention initiatives and efforts to prevent pathological aging),\n\nExclusion Criteria:\n\n* Participant unable to improve their lifestyle, according to the scales used in the study (participant with a maximum score on the ONAPS-PAQ scale and the food frequency score),\n* Participant without a postal or email address,\n* Participant with a life expectancy of less than 5 years.","45 Years",{"count":53,"type":23},290,"OBSERVATIONAL","Modifiable risk factors are estimated to account for 70% of cardiovascular diseases, 40% of Alzheimer's-type dementias, and 50% of type 2 diabetes cases. Numerous trials have evaluated interventions aimed at modifying these risk factors, whether through the promotion of healthy lifestyle choices (diet, physical activity, etc.) or specific activities (cognitive training, etc.). However, these trials have yielded inconsistent or modest results, potentially due to a failure to adopt the recommended lifestyle changes. To better tailor prevention interventions, it is therefore essential to have scales available that measure the barriers to and facilitators of lifestyle change.\n\nThe aim of this study is to develop and validate a Patient-Reported Outcome Measure (PROM) to assess the barriers to and facilitators of change following participation in a prevention program. The scale will be structured into three sub-scales (capability, opportunity, and motivation), administered one month after the prevention activity, and will distinguish between the adoption of new habits and the abandonment of existing ones.",[57,58],"Atheroscleroses","Geriatric",[60,61,62],"prevention","gériatrics","risk factors","NOT_YET_RECRUITING","2026-08-10",{"date":66,"type":34},"2026-08-14",{"date":68,"type":23},"2026-09-01",{"date":70,"type":23},"2028-06-01",{"name":40,"class":41},1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100651796","phase-4-discontinuation-or-continuation-of-sglt-2-inhibitors-before-cardiac-surgery-100651796","NCT07766109","Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery","Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes - DISCO Study","DISCO","Inclusion Criteria:\n\n* Adult patients scheduled to undergo cardiac surgery with cardiopulmonary bypass\n* patients treated with SGLT-2 inhibitors, including combined treatment with metformin, for at least 4 weeks\n* heart failure patients with a left ventricular ejection fraction strictly below 50%\n* patients enrolled in a social security scheme or equivalent\n* patients who have signed the informed consent form\n\nExclusion Criteria:\n\n* Treatment with SGLT-2 inhibitors initiated less than 4 weeks ago and other than empagliflozine or dapagliflozine\n* patients with a contraindication to SGLT-2 inhibitors: hypersensitivity, type 1 diabetes mellitus, and renal impairment with an estimated glomerular filtration rate below 25 mL\u002Fmin\u002F1.73 m²\n* acute conditions likely to call into question the continuation of SGLT2 inhibitor therapy (alone or in combination) at the time of inclusion, including in particular: shock state or acute tissue hypoxia (episode of hyperlactatemia \\> 3 mmol\u002FL within 7 days prior to inclusion); acute kidney injury within the previous 7 days (KDIGO stage ≥2); severe hepatocellular failure (factor V level \\\u003C 50%); acute alcohol intoxication within the previous 7 days or active alcohol use disorder without withdrawal\n* surgery scheduled within less than 3 days\n* surgery for active endocarditis within the last 3 months\n* patients on preoperative mechanical circulatory support\n* heart transplant surgery or implantation of an LVAD (left ventricular assist device)\n* chronic kidney disease patients with a glomerular filtration rate below 25 mL\u002Fmin\u002F1.73m²\n* heart failure patients with a preserved ejection fraction, equal to or greater than 50\n* pregnant or breastfeeding women\n* minors or adults under legal protection (guardianship or conservatorship)\n* patients participating in another interventional study patients who do not understand or speak French.",{"count":82,"type":23},434,[84],"PHASE4","SGLT-2 inhibitors are recommended treatments for managing heart failure patients. In cases of surgery, it is recommended to stop the treatment 3 days before surgery due to the risk of postoperative euglycemic diabetic ketoacidosis. However, several data suggest that it may be beneficial to maintain SGLT-2i treatment given the possibility of improving postoperative cardiovascular outcomes. Investigator team wish to conduct a randomized controlled trial to test the hypothesis that preoperative maintenance of SGLT-2i is superior to discontinuing them 3 days before surgery in improving postoperative cardiovascular outcomes.",[87,88],"Heart Failure","Cardiac Surgery",[90,91],"perioperative care","SGLT-2 inhibitor",{"date":66,"type":34},{"date":94,"type":23},"2026-10",{"date":96,"type":23},"2029-01",{"name":40,"class":41},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":24,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":121,"locationsCount":72},"100651781","study-of-cognitive-linguistic-profiles-the-role-of-executive-control-in-aphasia-100651781","NCT07766356","Study of Cognitive-Linguistic Profiles: The Role of Executive Control in Aphasia","Study of Cognitive-linguistic Profiles in Brain-injured Adults: the Role of Executive Control in Mild Aphasia.","P-CLAC","Inclusion Criteria:\n\n* Patient who has experienced a first ischemic stroke resulting in clinical symptoms within the last 3 months and is receiving care in the Physical Medicine and Rehabilitation department.\n* Score ≤ 31 on the conversational speech observation scale of the MEC test (Montreal Protocol for the Evaluation of Communication).\n* Patients with a BDAE score ≥ 3 (Boston Diagnostic Aphasia Examination - French version, Mazaux J.-M. \\[1990\\]); this score is the gold standard in aphasiology.\n* Native French-speaking patient capable of understanding oral or written instructions.\n\nExclusion Criteria:\n\n* Patients exhibiting behavior or a clinical condition incompatible with test administration, as assessed by the clinician.\n* Known major visual, auditory, or motor impairments incompatible with test performance.\n* Known neurodegenerative and\u002For neurodevelopmental disorders.\n* Known social cognition disorders (e.g., ASD).","65 Years",{"count":108,"type":23},30,[26],"In France, stroke affects 150,000 people annually and is the leading cause of acquired disability in adults; 10-12% of patients exhibit mild post-stroke aphasia, a condition defined by language difficulties.\n\nFew studies describe mild post-stroke aphasia, and none characterize the impairment of linguistic executive control in this population; consequently, its prevalence remains unknown. To date, the role of linguistic executive control in mild aphasia remains an open question.\n\nThe aim of this project is to investigate linguistic executive control impairment in stroke survivors with mild aphasia, provide an initial estimate of its prevalence, and demonstrate its interactions with other linguistic and communicative aspects, as well as with executive and attentional functions.",[112],"Stroke",[114,115,116],"stroke","aphasia","AVC",{"date":66,"type":34},{"date":68,"type":23},{"date":120,"type":23},"2028-09-08",{"name":40,"class":41},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":130,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":24,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":152,"locationsCount":72},"100651754","phase-4-analysis-of-the-performance-of-psma-emission-tomography-in-patients-with-prostate-cancer-treated-with-hifu-100651754","NCT07766122","Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU","Pilot Study Evaluating PSMA Positron Emission Tomography for Monitoring Clinically Significant Prostate Cancer After Focal HIFU Treatment","ECETEP","Inclusion Criteria:\n\n* Patient with prostate cancer\n* Age ≥ 70 years (HAS 2023)\n* Life expectancy \\> 5 years\n* Clinical stage Clinical stage T1c - T2a PSA \\\u003C 20 ng\u002Fml Biopsy :ISUP 2 unilateral on a maximum of 2 contiguous sextants with or without ipsilateral or contralateral focus ISUP1 single focus or multiple foci if only one ISUP 2 focus on targeted biopsy\n* Imaging Single lesion PIRADS 3 or 4 or 5 Volume of prostate gland \\\u003C 150 ml\n* Enrolled in a social security scheme\n* Signature of consent\n\nExclusion Criteria:\n\n* Evidence of extra-prostatic extension or invasion of the seminal vesicles.\n* Any condition that, in the judgement of the investigators, would interfere with the subject's ability to\n* provide informed consent, comply with study instructions, expose the subject to increased risk, or interfere with the interpretation of study results.\n* Patients deprived of their liberty or under legal protection (curatorship and guardianship, safeguard of justice)\n* Hypersensitivity to the active substances or to any of the excipients\n* Conditions contraindicating magnetic resonance imaging (MRI), such as the presence of internal metallic devices.\n* Chronic kidney disease with an eGFR ≤ 60 mL\u002Fmin\n* Liver failure","MALE","70 Years",{"count":108,"type":23},[84],"There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI in detecting clinically significant recurrent PaC after treatment with HIFU. The main objective was to evaluate the diagnostic performance of PSMA PET compared with MRI with reference to the gold standard of prostate biopsy one year after HIFU.",[136,137],"Prostate Cancer - Recurrent","Prostate Cancer (Diagnosis)",[139,140,141,142,143,144,145,146,147],"prostate cancer","focal treatment","focal therapy","high-intensity focused ultrasound (HIFU)","PET PSMA","prostate MRI","recurrence","post-treatment follow-up","functional nuclear imaging",{"date":66,"type":34},{"date":94,"type":23},{"date":151,"type":23},"2028-10",{"name":40,"class":41},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":24,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":72},"100587572","effect-of-anomia-rehabilitation-combined-with-metacognitive-training-in-patients-with-chronic-vascular-aphasia-100587572","NCT06930131","Effect of Anomia Rehabilitation Combined With Metacognitive Training in Patients With Chronic Vascular Aphasia","METALEX","Inclusion Criteria:\n\n* First cerebral infarction\n* Chronic phase (\\> 3 months)\n* Patient affiliated to a health insurance scheme\n* Usual french language\n* Severity score measures using the Boston Diagnostic Aphasia Examination battery scale corresponding to the mild or moderate level (score greater than or equal to 2)\n\nExclusion Criteria:\n\n* Contraindication to undergoing brain MRI\n* Cognitive impairment pre-existing stroke (CQI code \\> 3.4) (Law et al., 1995)\n* Chronic alcohol or drug abuse\n* Unstabilised psychiatric illness\n* Uncorrected sensory deficits\n* Diagnosed as having a progressive general pathology",{"count":161,"type":23},18,[26],"The postulate of this study is that rehabilitation combining linguistic and metacognitive training will result in a significant improvement in language performance correlated with changes in functional cerebral connectivity networks. In addition, it could potentiate the generalisation of effects to verbal and non-verbal communication skills, having a direct impact on patients' quality of life. This research is a prospective, randomized controlled, open-label, single-centre study. It is part of the management of patients with aphasia who have suffered a cerebral infarction and aims to evaluate the effect of combined language semantics\u002Fmetacognition rehabilitation.",[165,112],"Aphasia",[165,112,167,168,169],"Chronic","Cognitive rehabilitation","SCED",{"date":31,"type":34},{"date":172,"type":34},"2025-02-21",{"date":174,"type":23},"2027-12",{"name":40,"class":41},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":19,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":24,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},"100466214","impact-of-procalcitonin-guided-algorithm-on-early-discontinuation-of-antibiotic-therapy-100466214","NCT05350813","Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy","Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy in Pediatric Intensive Care Units : a Multicenter Randomized Controlled Trial","PRODISCO","Inclusion Criteria:\n\n* Neonates, infants and children hospitalized in Pediatric and Neonatal ICU and receiving intravenous antibiotics for less than 24 hours for an episode of suspected or proven community-acquired or nosocomial bacterial infection.\n* Written informed consent signed by both parents or legal guardians.\n* Affiliated to a social security scheme.\n* Parents French-speaking.\n\nExclusion Criteria:\n\n* Newborns \\\u003C72 hours old.\n* Neonates \\\u003C37 weeks postmenstrual age.\n* Age ≥18 years.\n* Pregnant or breastfeeding women.\n* Patients with cystic fibrosis.\n* Immunocompromised patients including patients with hereditary immunodeficiency, agranulocytosis (neutrophils count \\\u003C500\u002Fmm3), HIV infection with CD4 count \\\u003C200\u002Fmm3, sickle cell disease, those who have undergone splenectomy, those who have a history of solid organ or hematopoietic stem cell transplant, those with hemopathy or solid organ tumor treated with chemotherapy, and those on immunosuppressive drugs including systemic corticosteroids taken daily for at least 15 days prior to Day 0.\n* Inflammatory situations increasing PCT plasma concentrations in the absence of infection: burns, extracorporeal membrane oxygenation (ECMO), first 48 hours following an open-heart cardiac surgery with cardiopulmonary bypass.\n* Infections requiring prolonged antibiotic therapy: infected thrombophlebitis, infective endocarditis, mediastinitis, abscess or empyema (e.g. peritonsillar abscess, retropharyngeal abscess, adenophlegmon, retroauricular abscess, retroorbital abscess, pulmonary abscess, pleural empyema, liver abscess, splenic abscess, brain abscess, subdural empyema, extradural empyema, epidural abscess, intramuscular abscess), necrotizing dermohypodermitis or necrotizing fasciitis, osteomyelitis, osteitis, arthritis, spondylodiscitis, prostatitis, tuberculosis, meningitis except those caused by Haemophilus and Meningococcus, infection on a device excluding intravascular catheter, endotracheal tube, tracheostomy, and urinary catheter.\n* Antibiotic for prophylaxis.\n* Children previously included in an interventional study in progress.","3 Days","17 Years",{"count":187,"type":23},296,[26],"In this randomized controlled open-label trial, conducted in 7 French Pediatric and Neonatal Intensive Care Units (ICUs), investigator team hypothesize that the use of a procalcitonin (PCT)-guided algorithm to discontinue antibiotic treatment will decrease antibiotic duration in critically ill children treated for a suspected or proven bacterial infection. Two hundred and ninety-six eligible patients will be randomly assigned in two groups: either PCT-guided or standard-of-care antibiotic discontinuation, and monitored over 28 days, until the end of their hospitalization, or up to the end of antibiotic treatment for bacterial infection recurrence occurring up to 28 days after the day of randomization.",[191],"Bacterial Infections",[193,194,195,196,197],"procalcitonin","Children","Pediatric Intensive Care Unit","Procalcitonin-guided antibiotic therapy","Algorithm",{"date":31,"type":34},{"date":200,"type":34},"2023-05-02",{"date":202,"type":23},"2027-02-02",{"name":40,"class":41},8,{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":24,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":72},"100458474","physicians-performance-after-night-shifts-100458474","NCT05250089","Physicians Performance After Night Shifts","Performance of Emergency Physicians in the Management of Critical Situations Twenty-four Hours After the End of a Night Shift","URGENCE24","Inclusion Criteria:\n\n* be an emergency doctor with an emergency medicine capacity,\n* work full time in the emergency medicine center of the Toulouse University Hospital\n* on call in at least one of the emergency reception services of the Toulouse University Hospital\n* to have given his non-opposition to participate and his authorization of right to his image and his voice within the framework of the research\n\nExclusion Criteria:\n\n* non-emergency doctor\n* emergency doctor not on call in at least one of the emergency services of the Toulouse University Hospital\n* professional with a declared personal or professional conflict with one of the members of the group","100 Years",{"count":215,"type":23},40,[26],"Emergency medicine is one of the professional activities integrating a night activity into working time. Concerns about the sleep deprivation that this activity generates have been growing for the past thirty years. However, at present, the pace - duration and repetition - of this activity does not yet seem to be optimized, and therefore continues to be the subject of questions in terms of safety of care and quality of life at work. One of the peculiarities of emergency medicine is that doctors have to work in a crisis situation. A situation is qualified as critical for a patient when his state of health is unstable, and with an evolution which can be rapidly pejorative. Crisis situations are at the heart of the emergency room profession, and due to their potential seriousness for the patients, it must be managed in all circumstances.\n\nTo cope with a crisis situation, a doctor needs to be efficient. However, performance calls for two types of skills: technical skills on one hand, and non-technical skills on the other.\n\nThis study therefore aims to answer the following question: are the non-technical skills of emergency physicians in the management of a crisis situation affected twenty-four hours after the end of a night shift? The study assesses the performance of emergency physicians via complex simulations at two time frames : 24h after a night shift (the post recovery performance simulation) and another time were the participant did not have night shifts in less than 3 nights (usual performance simulation).",[219],"Performance",[221,222,223,224],"emergency","night shift","efficiency","physicians",{"date":31,"type":34},{"date":227,"type":34},"2024-01-16",{"date":229,"type":23},"2028-01-16",{"name":40,"class":41},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":213,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":72},"100436000","semantic-rehabilitation-for-patients-with-primary-progressive-semantic-aphasia-100436000","NCT04957537","Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia","Evaluation of the Effect of a Semantic Rehabilitation in Patients in the Mild to Moderate Stage of Primary Progressive Semantic Aphasia : a SCED Study","SCED-APPvs","Inclusion Criteria:\n\n* Have a diagnosis of primary progressive semantic aphasia according to the criteria of Gorno-Tempini et al (2011) (Appendix A)\n* Being in the mild to moderate stage of dementia (MMSE score between 10 and 28) (Crum et al., 1993; Derouesné et al., 1999)\n* Common French\n* Being affiliated to a social security scheme\n* Being over the age of 18 years old\n\nExclusion Criteria:\n\n* Have significant uncorrected visual and\u002For hearing impairment\n* Have a history of brain injuries, major head trauma\n* Have untreated psychiatric disorders\n* Have significant motor and\u002For comprehension problems that make it impossible to take part in the study\n* Chronical use of drugs and\u002For alcohol\n* Under guardians or curators\n* Severe depression (Beck's depression scale score \\> 9) (Beck \\& al., 1961)",{"count":240,"type":23},15,[26],"This project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the SCED methodology.",[244],"Primary Progressive Aphasia",[246,247,248,249,250,251,252,253,254],"Semantic primary progressive aphasia","semantic variant (svPPA)","speech therapy","anomia","metacognition","Single Case Experimental Design","technology","naming","speed of lexical access",{"date":31,"type":34},{"date":257,"type":34},"2021-09-20",{"date":259,"type":23},"2027-03-20",{"name":40,"class":41},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":269,"targetDuration":4,"studyType":24,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":72},"100428460","evolution-of-balance-and-vestibular-function-in-patients-treated-with-gammaknife-radiosurgery-for-vestibular-schwannoma-100428460","NCT04859335","Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma","Prospective Study : Long-term Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma EQUI-GAMMA","EQUI-GAMMA","Inclusion Criteria:\n\n* Vestibular schwannoma's Patients for whom an indication of gammaknife radiosurgery was determined in a dedicated multidisciplinary consultation meeting, having not received previous treatment for this schwannoma.\n* Patient affiliated to Social Security\n* No opposition to participation\n\nExclusion Criteria:\n\n* History of prior treatment for the presented vestibular schwannoma (surgery, fractional radiotherapy)\n* History of otological or otoneurological pathology associated with schwannoma\n* Patient with type 2 neurofibromatosis\n* Patient under legal protection\n* Pregnant or breastfeeding women",{"count":270,"type":23},50,[26],"Vestibular schwannomas are benign lesions of the ponto-cerebellar angle that are potentially dangerous because of their growth in a cramped space and the compressive phenomena they can cause. Stereotactic Gammaknife radiosurgery is a treatment option that can be offered for evolutive schwannomas smaller than 2.5-3 cm in size. It allows tumor stabilisation in 85% of cases with less than 1% facial nerve damage risk.\n\nThere are controversial results regarding hearing preservation : percentages vary between 25 and 80% in the literature, depending on the criteria used and the post-treatment delay.\n\nFew studies have investigated changes in vestibular function and the impact on balance of radiosurgery, and their results are variable.\n\nThese controversial results lead us to comprehensively assess the vestibular function and balance of these patients using a balance-specific quality of life questionnaire, in addition to objective overall vestibular assessments of vestibular function.",[274],"Vestibular Schwannoma",[274,276,277,278],"Gammaknife radiosurgery","Dizziness","Balance",{"date":31,"type":34},{"date":281,"type":34},"2021-05-21",{"date":283,"type":23},"2028-12-01",{"name":40,"class":41},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":293,"targetDuration":4,"studyType":24,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":311},"100568924","phase-4-jak-inhibitor-dose-tapering-strategy-study-100568924","NCT06687551","JAK Inhibitor Dose TAPering Strategy Study","JAK Inhibitor Dose TAPering Strategy Study in Low Disease Activity Rheumatoid Arthritis Patients","JAK-TAP","The inclusion criteria will be\n\n1. Aged ≥ 18 years at baseline.\n2. Rheumatoid arthritis defined by the ACR\u002FEULAR criteria.\n3. Treated with a JAK inhibitor, full dose for at least 6 months.\n4. The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion.\n5. Being in LDA (CDAI≤10) for at least 6 months.\n6. With a CRP level below the laboratory standard within the month before the inclusion visit.\n7. Women of childbearing potential (WCBP) must have a negative pregnancy test before starting study\n\nThe non-inclusion criteria will be:\n\n1. Concomitant disease needing to be treated by the JAK inhibitor at full-dose (for example inflammatory bowel disease).\n2. Patient with a history of JAK-inhibitor dose reduction\u002Fspacing before enrollment in the study with the JAK-inhibitor currently being taken.\n3. Evidence of flare-up within the last 6 months prior to the inclusion.\n4. Patient who received glucocorticoids \\> 5mg\u002Fday in the 3 months prior the inclusion because of the disease activity of the RA.\n5. Patient requiring corticoid joint injections in the 3 months prior to inclusion or with scheduled joint injections, to control disease activity.\n6. Patient at risk for complication according to the ANSM (60) (current or past smokers, patients at risk of VTE, cancer or major cardiovascular problems, aged ≥ 65 years) at baseline AND currently taking baricitinib or filgotinib.\n7. Patient taking associated bDMARD (including anti-TNF, anti-IL6, anti-CD20, abatacept, anti-IL17, anti-IL12\u002F23, anti-IL23, anti-IL1, anti-BAFF, anti-IL5 pathways).\n8. Patient taking immunotherapy for neoplasia.\n9. Surgery scheduled in the next 12 months.\n10. Fibromyalgia according to the physician's opinion.\n11. Anticipated poor compliance with the strategy.\n12. Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation.\n13. Alcohol and\u002For drug misuse as determined by the investigator.\n14. Pregnancy or breastfeeding.\n15. Non-affiliation to the French Social Security System.\n16. Patient unwilling to sign the informed consent form.\n17. Patient under legal protection.",{"count":294,"type":23},308,[84],"This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose.\n\nParticipants will:\n\n* Either take\n\n  1. JAK inhibitor dose-tapering strategy.\n  2. JAK inhibitor continuous therapy strategy.\n* Visit the clinic once every 3 months for checkups and tests\n* Keep a diary of their treatment intake and symptoms",[298],"Rheumatoid Arthritis (RA",[300,301,302],"JAK-inhibitor","dose reduction","Rheumatoid arthritis","2026-08-04",{"date":305,"type":34},"2026-08-07",{"date":307,"type":34},"2025-06-06",{"date":309,"type":23},"2029-04-01",{"name":40,"class":41},24,{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":24,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":72},"100522061","cognitive-remediation-of-working-memory-post-head-trauma-100522061","NCT06077695","Cognitive Remediation of Working Memory Post Head Trauma","Cognitive Remediation of Working Memory After Moderate to Severe Head Trauma. a SCED Study.","Meta-SCED","Inclusion Criteria:\n\n* Moderate or severe head trauma, defined by an initial Glasgow score ≤ 12\u002F15, duration of post-traumatic amnesia superior to 24 hours and\u002For the presence of abnormalities on brain imaging,\n* Moderate or severe head trauma occurring within a period greater than or equal to 3 months,\n* Working memory complaints assessed by the Working Memory Questionnaire,\n* Patients with a working memory disorder in at least one of the following tests: Digit Memory subtest WAIS-IV (standard deviation ≤ -2) , PASAT (percentile ≤ 10), Brown-Peterson (standard deviation ≤ -2).\n\nExclusion Criteria:\n\n* Presence of aphasia, apraxia or severe neglect demonstrated by standardized neuropsychological tests during the inclusion visit: language - oral naming of BECS-GRECO images, ideational praxis and ideomotor , neglect - bell test,\n* Insufficient visual or auditory abilities and oral and written expression to carry out neuropsychological tests,\n* Severe depression assessed by the Beck Depression Inventory (BDI)\n* Chronic alcoholic poisoning, drug addiction,\n* Progressive general illness,\n* Progressive psychiatric or neurological condition leading to cognitive impairment,\n* Hospitalization for a neurological pathology since the acute phase of the qualifying event,\n* Patient requiring surgery during study participation.\n* Pregnant or breastfeeding women","60 Years",{"count":322,"type":23},9,[26],"Patients with working memory deficits due to a moderate to severe head injury will undergo a 5 month protocol including cognitive remediation with numerous exercises, transcranial direct current stimulation (tDCS), and therapeutic education.",[326],"Head Trauma",[328,329,330],"working memory","cognitive remediation","transcranial direct current stimulation",{"date":305,"type":34},{"date":333,"type":34},"2025-11-06",{"date":335,"type":23},"2027-07-06",{"name":40,"class":41},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":364},"100648866","endoscopic-treatment-100648866","NCT07727824","Endoscopic Treatment","Endoscopic Treatment With 3D Customized Versus Standard Stent for Non-malignant Airway Stenoses: A Randomized Controlled Trial","ETNA","Inclusion Criteria:\n\n* Age \\>18 years,\n* Central non-malignant symptomatic (dyspnea \\> grade 2 mMRC or post-stenotic infection) airway stenosis with silicone stent implantation indication (viable downstream airways, pulmonary artery and parenchyma),\n* To have access to a personal telephone for the teleconsultation scheduled in the protocol,\n* Informed consent signed,\n* Health insurance beneficiary.\n\nExclusion Criteria:\n\n* Acute respiratory distress,\n* Mechanical ventilation,\n* Contraindication to rigid bronchoscopy: severe coagulation disorders that cannot be corrected, anticoagulant or antiplatelet therapy other than aspirin within 5 days prior to the stent implantation,\n* Malignant stenosis,\n* Pregnancy or breast-feeding,\n* A situation in which emergency or semi-emergency intervention (less than 48 hours) may be anticipated (like an acute respiratory distress for example),\n* Patient under legal protection, - Participation in another study with an exclusion period still in progress,\n* Impossibility of giving the person informed information and of ensuring the subject's compliance due to impaired physical and\u002For psychological health.",{"count":346,"type":23},96,[26],"The placement of an endoprosthesis in the airways leads to rapid and dramatic clinical improvement in the majority of cases of central airway obstruction. However, the limited diversity of device shapes available on the market is a major limitation, as these devices are poorly adapted, or not adapted at all, to the patient's anatomy. The main consequences of this lack of congruity are stent migration and granulomatous inflammatory reactions. The investigators hypothesized that personalized endoprostheses could significantly reduce the complication rate and improve tolerability. In this randomized controlled trial, the investigators propose to evaluate whether personalized endoprostheses allow for better management of non-malignant central airway stenoses by comparing this new approach to standard care.",[350,351],"Stenoses","Dyspnea",[353,341,354,355],"Non-malignant Airway stenoses","3D customized stent","stent","2026-07-21",{"date":358,"type":34},"2026-07-27",{"date":360,"type":23},"2027-01",{"date":362,"type":23},"2031-01",{"name":40,"class":41},6,{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":72},"100560374","predictive-factors-for-occlusal-changes-in-obstructive-sleep-apnea-treatment-with-mandibular-advancement-appliance-100560374","NCT06576310","Predictive Factors for Occlusal Changes in Obstructive Sleep Apnea Treatment With Mandibular Advancement Appliance","Evaluation of Predictive Factors for Dental Occlusal Changes in the Treatment of Obstructive Sleep Apnea With Mandibular Advancement Appliance","APNEAMOUVE","Inclusion Criteria:\n\n* Patient with complete dentition (up to second molars)\n* Polysomnography or polygraphy\n* Diagnosis of OSA\n* Patient receiving OAM treatment at the Odontology Department of Toulouse University Hospital\n* Patient with contemporary panoramic and lateral cephalometric X-rays (common practice) taken at the time of orthotic treatment\n* Individual affiliated with or covered by a social security scheme\n* Voluntary, informed, written consent, signed by both participant and investigator (prior to inclusion and any necessary research-related examinations).\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Pregnant or breastfeeding patient\n* Patient with curators, guardians, or legal protection",{"count":374,"type":23},118,"This research addresses obstructive sleep apnea syndrome (OSAS), affecting 6-12% of French adults, often treated with mandibular advancement devices (MADs). MADs may lead to occlusal modifications, causing a 50% treatment abandonment rate. The study employs surface electromyography to assess masticatory muscle activity before and during MAD use, correlating it with occlusal changes after 6 months. The primary goal is to determine dental displacement profiles post-6-month MAD treatment, providing insights for personalized care and minimizing treatment failures.",[377],"Obstructive Sleep Apnea Syndrome",[379,380,381,382],"MAD therapy","side effect","Dental occlusion","electromyography",{"date":384,"type":34},"2026-07-23",{"date":386,"type":34},"2025-01-06",{"date":388,"type":23},"2027-10-06",{"name":40,"class":41},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":398,"briefSummary":400,"conditions":401,"keywords":404,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":72},"100492963","phase-3-evaluation-of-botulinum-toxin-type-a-in-the-treatment-of-buergers-disease-100492963","NCT05698979","Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease","BETOX","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. patient with Buerger's disease according to Olin criteria (ref)\n3. with digital ischemia with critical upper or lower limb ischemia criteria defined as Upper limb: pain and\u002For trophic disorders for at least 15 days AND digital pressure less than 50 mmHg Or TCPO2 30 mmHg) Or\u002Fand Lower limb: pain and\u002For trophic disorders for at least 15 days AND ankle pressure less than 50 mmHg (70 mmHg if diabetes), or 30 mmHg at the toe (50 mmHg if diabetes) or TCPO2 30 mmHg).\n4. Ability to attend study visits\n5. Ability to complete daily study agenda\n6. Ability to give free and informed consent\n7. Membership of a Social Security scheme\n\nExclusion Criteria:\n\n1. History of myasthenia gravis or Eaton-Lambert syndrome\n2. History of inflammatory myositis for less than 2 years or pre-existing motor neuron disease or superior limb neuropathy.\n3. Known allergy to botulinum toxin or cream lidocaine, albumin or inhaled nitrous oxide\u002Foxygen.\n4. Progressive infection of one hand or foot\n5. Aminoglycoside treatment\n6. Pregnant or nursing women\n7. History of vascular surgery of surgical sympathectomy of upper or lower limb\n8. Revascularization procedure considered within 3 months of inclusion\n9. Risk of major amputation within 3 months of inclusion\n10. Iloprost expected within one month of study treatment\n11. Hyperbaric chamber sessions scheduled within one month of study treatment\n12. Life expectancy less than 6 months\n13. Contraindication to one or more of the following products: BOTOX 100 UNITS ALLERGAN, LIDOCAINE\u002FPRILOCAINE 5%, cream or NITROUS OXIDE MEDICINAL\n14. Patients treated by class III anti arhythmic drugs for example amiodarone 15 ) Patient with guardians, curators, or protection of justice",{"count":204,"type":23},[399],"PHASE3","The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.",[402,403],"Buerger Disease","Raynaud Syndrome",[405,406,407,408,409,410],"botulinum toxin A","botox","feasibility","raynaud","buerger","tolerance",{"date":384,"type":34},{"date":413,"type":23},"2027-01-01",{"date":415,"type":23},"2028-02",{"name":40,"class":41},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":18,"sex":19,"minAge":320,"maxAge":213,"enrollmentInfo":425,"targetDuration":4,"studyType":24,"phases":427,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":72},"100593497","phase-2-biomarkers-of-the-locus-coeruleus-nucleus-links-with-early-tau-pathology-cognition-and-alzheimers-disease-risk-100593497","NCT07007208","Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk","Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk.","Locus-Tau","Inclusion Criteria:\n\n* Participant in the INSPIRE-T cohort\n* Normal cognitive assessment\n* MMSE score ≥ 27 out of 30 (Mini-Mental State Examination)\n* Normal visual abilities (in corrected or uncorrected vision)\n* Normal motor skills\n\nExclusion Criteria:\n\n* Subjects with a contraindication to MRI exam\n* Subjects with a known allergic reaction to the PET radiopharmaceutical (\\[18F\\] Flortaucipir) or any of its excipients\n* Subjects with an ophthalmological pathology making oculometric measurements difficult\n* Subjects with a neurodegenerative condition or a history of cerebral ischemia\n* Subjects with a psychiatric disorder and a PHQ-9 score \\> 10 or under treatment with NRI",{"count":426,"type":23},100,[428],"PHASE2","Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.",[431],"Alzheimer Disease",[433,434,435,436,437],"PET","MRI","occulometry","locus coeruleus","Alzheimer disease","2026-07-15",{"date":440,"type":34},"2026-07-17",{"date":442,"type":34},"2026-02-02",{"date":444,"type":23},"2029-01-31",{"name":40,"class":41},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":72},"100507879","evaluation-of-a-cardiac-coherence-session-to-reducing-patients-anxiety-during-a-mri-examination-100507879","NCT05893121","Evaluation of a Cardiac Coherence Session to Reducing Patients' Anxiety During a MRI Examination","Evaluating the Contribution of a Cardiac Coherence Session to Reducing Patients' Anxiety During a Medical Magnetic Resonance Imaging Examination","RESP-IRM","Inclusion Criteria:\n\n* Person affiliated to or benefiting from a social security scheme;\n* Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research);\n* Patient to undergo an MRI examination of the upper half of the body\n* Patient over 18 years old\n* Patient with a high level of anxiety (score ≥ 4) in relation to MRI\n\nNon-inclusion Criteria:\n\n* Patient under legal protection or under another protection regime (guardianship, curatorship).\n* Sedated or unconscious patient\n* Patient performing an emergency MRI examination\n* Patient with a level of French language that does not allow sufficient understanding for the completion of questionnaires\n\nExclusion criteria:\n\n\\- STAI Y-A score \\\u003C 46 (insignificant or low anxiety)",{"count":455,"type":23},60,"The present project aims at conducting a proof of concept study to explore the pertinence of a single session of cardiac coherence, carried out in patients prior to an MRI examination and presenting anxiety in relation to this examination, to reduce their level of anxiety and thus improve the course of the examination.",[458],"Anxiety",[460,461],"cardiac coherence","improving patient management",{"date":463,"type":34},"2026-07-16",{"date":465,"type":34},"2023-12-08",{"date":467,"type":23},"2026-09-30",{"name":40,"class":41},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":24,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":478},"100631423","pilot-study-home-use-of-wearable-grasping-neuroprosthesis-in-vascular-hemiparesis-100631423","NCT07500480","Pilot Study: Home Use of Wearable Grasping Neuroprosthesis in Vascular Hemiparesis","Pilot Study Evaluating the Usability and Functional Impact of Prolonged Home Use of a Wearable Grasping Neuroprosthesis in Subjects With Vascular Hemiparesis - GRASP-HOME","GRASP-HOME","Inclusion CriteriA\u002F\n\n* Adult patient who participated in and completed the GRASP-AGAIN study and achieved functional improvement through the use of NAP.\n* Motor deficit of an upper limb resulting from a single ischemic or hemorrhagic stroke, hemispheric or brainstem, confirmed by brain imaging (CT scan or MRI);\n* Brain lesion occurring more than one month prior;\n* Presence of at least one of the following two disabilities:\n\n  * Inability to actively extend the long fingers (open the hand) to actively grasp an empty glass (upper and lower diameters of 7 and 6 cm respectively, height of 12 to 15 cm, weight of 125 g, identical to the material used for the Action Research Arm Test scale) with a palmar grip, without the aid of the other hand, while the subject is able to hold the glass passively in the hand;\n  * Inability to actively extend the thumb to grasp the handle of a soup spoon (flat, like a key) without the aid of the other hand, using a thumb-index finger pulp-lateral grip (grasping task in the Wolf Motor Function Test), while the subject can passively hold the handle of a spoon or a key previously placed between the thumb and index finger;\n* Patient receiving care within the standard healthcare pathway;\n* Ability to sit in a chair and remain focused for at least 1.5 hours;\n* Free, informed, and written consent signed by the participant and the investigator (no later than the day of enrollment and before any examination required for the research);\n* Individual affiliated with or covered by a social security scheme\n\nExclusion Criteria:\n\n* The person is in labor or breastfeeding;\n* The person is pregnant, the diagnosis being guided by questioning (date of last menstrual period, desire for pregnancy, contraception) and possibly confirmed by a blood test for beta hCG;\n* Musculotendinous contractures or joint stiffness of the fingers and wrist preventing passive opening of the fingers;\n* Limited approach ability preventing the hand from being positioned in front of the abdomen (without contact) at the level of the midline sagittal plane, while the subject is seated;\n* Paretic pain in the upper limb limiting the performance of the standardized grasping task;\n* Major sensory disturbances corresponding to a Somatosensation subscore of the modified Erasmus Nottingham Sensory Assessment French version (EmNSA-F, see Appendix A) upper limb \\\u003C10\u002F44;\n* Severe aphasia with a Boston Diagnostic Severity Aphasia Examination Severity Scale score ≤ 3, see Appendix B, indicating that there may be a marked decrease in verbal fluency or ease and rapidity of comprehension, without significant limitation of expression or communication;\n* Known gestural apraxia, within the limits of the subject's motor abilities (ideomotor apraxia, ideational apraxia, dressing apraxia, or reflexive apraxia);\n* Unilateral spatial neglect demonstrated with the bell test (see Appendix B'), if the difference between omissions in the left and right visual fields is greater than or equal to 6;\n* The extensor digitorum communis and\u002For extensor pollicis longus muscles cannot be stimulated with the neuroprosthesis, meaning that sufficient extension of the long fingers and\u002For thumb for grasping tasks is not achieved with electrical stimulation well tolerated by the patient;\n* The person has a pacemaker;\n* Presence of uncontrolled epilepsy;\n* Presence of unstable cardiovascular disease (coronary artery disease, severe hypertension, heart failure);\n* Presence of a dermatological condition contraindicating the application of surface electrodes;\n* The person is participating in another research study with an ongoing exclusion period;\n* The person is under legal guardianship or conservatorship;\n* The person refuses to sign the consent form;\n* It proves impossible to provide the person with informed consent and ensure their compliance due to impaired physical and\u002For psychological health.",{"count":478,"type":23},2,[26],"Stroke is the leading cause of acquired motor disability in adults. Six months post-stroke, 50% of patients have not regained active finger extension, and 80% retain a grasping deficit, most commonly an inability to actively open the hand. This motor impairment significantly impacts daily activities, social interactions, professional life, and overall quality of life. Despite numerous treatments available in rehabilitation centers during the subacute phase, no functional assistive devices are currently usable at home. Since 2018, our team, in collaboration with the CAMIN-INRIA team, has developed a Grasp Neuroprosthesis (GNP). This device uses functional electrical stimulation to restore grasping function in hemiplegic subjects, enhancing autonomy in daily bimanual tasks. The GNP has been evaluated in hospital settings through two studies, defining preferred control modalities and demonstrating significant functional impact. Additionally, another study tested a wearable version of the GNP used autonomously at home for two months. This study showed the feasibility and functional benefits of home GNP use, provided the device is customizable to the patient's characteristics and environment. Initial results indicate improved quality of life and increased autonomy with GNP use. The wearable GNP consist of a forearm orthosis made of soft fabric, integrating an electrode array and a stimulator (CE medical marking for home use), connected via WiFi to a microprocessor positioned in a pouch. The microprocessor incorporates information from inertial measurement units and a microphone, allowing the user to control the electrical stimulator on demand. The stimulation targets the extensor muscles of the long fingers and the thumb, enabling the user to open the hand on demand. We propose extending the home use of the GNP to two patients for one year. Each subject will be followed for one year, with evaluations in a hospital setting at the beginning and end of the period, monthly follow-ups at home throughout the year, and on-demand video consultations.",[112,482],"Réhabilitation","2026-06-26",{"date":485,"type":34},"2026-06-30",{"date":487,"type":34},"2026-04-20",{"date":489,"type":23},"2027-04-30",{"name":40,"class":41},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":499,"enrollmentInfo":500,"targetDuration":502,"studyType":54,"phases":4,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":72},"100644700","biological-collection-on-emerging-infectious-diseases-and-their-treatments-100644700","NCT07674550","Biological Collection on Emerging Infectious Diseases and Their Treatments","A Biological Sample Collection Established to Support Pathophysiological Research on Emerging and Potentially Emerging Infectious Diseases, as Well as Their Therapeutic Management.","COMETE","Inclusion Criteria:\n\n* Patients aged 18 years or over\n* Patients or individuals who have been exposed, are at risk of exposure, or are at risk of complications if exposed, or who are suspected of having, or are diagnosed with, an infectious disease considered to be emerging or at risk of emerging\n* Patients receiving, or likely to receive, innovative treatments for the infection (new therapeutic molecules, checkpoint inhibitors, cell therapies, etc.)\n* Patients or individuals receiving, or likely to receive, vaccines or other preventive therapeutic strategies\n* Pregnant and breastfeeding women may be included.\n\nExclusion Criteria:\n\n\\- Patients under a legal guardianship arrangement (guardianship, curatorship or court-ordered guardianship)","99 Years",{"count":501,"type":23},5300,"10 Years","Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs). Advances in the treatment of cancers, malignant haematological disorders and immune-mediated inflammatory diseases are also contributing to the creation of new infectious risks among immunocompromised patient populations.\n\nThe COVID-19 pandemic has shown that structuring research prior to any outbreak is essential for the rapid implementation of responses to the emergence of an EID. The unpredictability of an EID's occurrence necessitates the planning of research projects in advance. A key element in this planning is the development of a collection of biological samples, providing a structured and immediately deployable resource for conducting pathophysiological and therapeutic research aimed at:\n\n* Analyze the biological determinants of the microbe and the resulting infection\n* Develop new tools for identification and characterization\n* Study the factors (biomarkers\u002Fsignatures) associated with individual patient susceptibility and response to treatment (personalized medicine)\n* Understand the pathophysiology of infection to identify new targets for diagnostic, curative and preventive treatment\n* Monitor the efficacy of curative and preventive treatments",[505],"Emerging Infectious Diseases and Their Treatments",[507,508,509,510,511,512,513,514],"Infectious diseases","acute respiratory infections","arboviral infections","infections of immunosuppressed patients","multi-resistant bacteria","orphan infectious diseases","disease X","new therapies","2026-06-24",{"date":517,"type":34},"2026-06-29",{"date":519,"type":23},"2026-06-15",{"date":521,"type":23},"2036-06-14",{"name":40,"class":41},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":532,"conditions":533,"keywords":538,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":72},"100639802","platelets-and-extracorporeal-membrane-oxygenation-veno-venous-100639802","NCT07580469","Platelets and Extracorporeal Membrane Oxygenation Veno-venous","Study of PLATelet Functions and Risk Factors for Hemorrhagic Complications in Patients on Extracorporeal Membrane Oxygenation Veno-venous: Prospective Monocentric Cohort","PLAT-VV-ECMO","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)\n* Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO\n* Equipped with an arterial catheter for blood sampling\n* Ability to undergo the 4 blood draws relevant to the study\n* Receiving therapeutic anticoagulation with unfractionated heparin\n* Enrolled in a social security program or equivalent\n* No measures for Limitation and Withdrawal of Therapy have been implemented\n\nExclusion Criteria:\n\n* Minors\n* Patients under court-appointed guardianship or conservatorship\n* Pregnant or breastfeeding women\n* Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia\n* Platelet transfusion within 7 days prior to enrollment\n* Indication for immediate emergency ECMO preventing blood sampling before placement\n* Post-cardiotomy\n* Patient on antiplatelet therapy\n* Severe thrombocytopenia \\\u003C50 G\u002FL\n* Other invasive mechanical support such as Impella®, intra-aortic balloon pump, or Left Ventricular Assist Device (LVAD)",{"count":215,"type":23},"In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.",[534,535,536,537],"Extracorporeal Membrane Oxygenation Complication","Hemorrhage","Blood Platelet Disorder","Thrombosis",[539,540,541,542,543],"VV-ECMO","Platelets","Thrombopathy","thrombo-haemorrhagic complications","thrombo-inflammation",{"date":517,"type":34},{"date":546,"type":23},"2026-09",{"date":548,"type":23},"2028-12-31",{"name":40,"class":41},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":559,"conditions":560,"keywords":562,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":72},"100580671","impact-of-variation-of-oxydo-reduction-potential-in-cardiac-surgery-on-post-operative-outcome-100580671","NCT06840327","Impact of VARIation of OXYdo-reduction Potential in Cardiac Surgery on Post-operative Outcome","VARIOXY","Inclusion Criteria:\n\nPatients over 18 years of age Scheduled cardiac surgery patients undergoing bypass surgery with saphenous vein harvesting.\n\nPatients able to understand the protocol; Patients able to express non-opposition to participating in the study Patients affiliated to a social security system or equivalent.\n\nExclusion Criteria:\n\nEmergency surgery patients. Pregnant or breast-feeding women. Patients deprived of their freedom or under legal protective measures.",{"count":558,"type":23},120,"Observational, prospective, monocentric study conducted in the cardiac surgery department about biological markers to predict the short-term outcome of heart surgery patients.",[88,561],"Extracorporeal Circulation",[563,564,565,566,567],"extracorporeal circulation","cardiac surgery","biological markers","Redox balance","post-operative outcome",{"date":517,"type":34},{"date":570,"type":34},"2025-10-07",{"date":38,"type":23},{"name":40,"class":41},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":583,"briefSummary":584,"conditions":585,"keywords":590,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":72},"100563531","combined-whole-brain-structural-and-functional-mri-for-the-prediction-of-neurological-recovery-after-cardiac-arrest-100563531","NCT06617377","Combined Whole-brain Structural and Functional MRI for the Prediction of Neurological Recovery After Cardiac Arrest","Use of Brain Structural and Functional Connectomes for the Prediction of Neurological Recovery in Coma Patients After Cardiac Arrest","ARISE","Inclusion Criteria:\n\n* Adult patients (male or female ≥ 18 years).\n* Coma, as indicated by a Glasgow Coma Scale (GCS) ≤ 8 (motor score ≤ 2) immediately after CA resuscitation and before sedation onset.\n* Persisting unconsciousness, defined as the inability to obey verbal commands, after at least 72 hours from complete withdrawal of sedation in normothermia conditions.\n* Written informed consent from patient's legal representative.\n* Affiliation or beneficiary to the French social security system.\n\nExclusion Criteria:\n\n* Brain death.\n* Coma explained by other cause than CA.\n* Likely poor neurological outcome based on early predictors, following ERC-ESCIM 2021 recommendations. In a comatose patient with GCS motor score ≤ 3 at ≥ 72 h from ROSC, in the absence of confounders, the identification of at least two of the following: bilaterally absent pupillary light and corneal reflexes at ≥ 72h, bilaterally absent N20 SSEP ≥ 24h; neuron-specific enolase (NSE) \\> 60 μg\u002Fl at 48h and\u002For 72h, status myoclonus ≤72h.\n* Decision of WLST previous to patient recruitment, based on early predictors of poor neurological outcome, age, co-morbidity, general organ function and patient's preferences.\n* Life expectancy shorter than 6 months based on pre-morbid conditions.\n* Former neurological functional disability (mRS \\> 2 before CA).\n* MRI contraindication: medical material not MRI compatible, claustrophobia\n* Known hypersensitivity to gadoteric acid, meglumin or any drug containing gadolinium\n* Severe kidney failure defined as a KDIGO score \\> 3 (glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2 or renal replacement therapy).\n* Hemodynamic shock or severe respiratory failure precluding patient's transport and MRI scanning.\n* Pregnancy or nursing woman.\n* Patient under juridical protection.",{"count":582,"type":23},263,[26],"To assess the performance of a predictive model resulting from the analysis of sMRI\u002FfMRI\u002Fcontrast-enhanced MRI-derived personalized connectomic data, as compared with standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) collected ≥ 72h from sedation withdrawal and in normothermia condition, to predict anoxoischemic coma neurological outcome at 6 months.",[586,587,588,589],"Coma","Cardiac Arrest","Disorder of Consciousness","Neurologic Disorder",[591,592,593,594,595,596],"prognosis","coma","cardiac arrest","Structural MRI","resting-state","cognitive motor dissociation",{"date":517,"type":34},{"date":599,"type":34},"2026-03-16",{"date":601,"type":23},"2029-09",{"name":40,"class":41},{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":18,"sex":19,"minAge":610,"maxAge":611,"enrollmentInfo":612,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":72},"100645018","measuring-the-evolution-of-speech-perception-in-noise-in-realistic-sound-environments-according-to-age-100645018","NCT07675941","Measuring the Evolution of Speech Perception in Noise, in Realistic Sound Environments According to Age","SI 360","Inclusion Criteria:\n\n* Children with normal hearing (average hearing thresholds at 250 Hz, 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz less than 20 dB)\n* Be between 7 and 15 years old\n* Be a native French speaker, without bilingualism\n* Have typical development, as assessed by a school level corresponding to their age;\n* No objection from at least one of the two legal guardians\n* Legal guardian registered with social security\n* Able to understand instructions and information provided\n\nExclusion Criteria:\n\n* Inability of the child to respond to tests\n* Abnormal hearing thresholds\n* Speech disorder treated by speech therapist\n* Inability to understand instructions \u002F to respond to tests\n* Neurological conditions\n* Multiple disabilities\n* Ongoing treatment that may affect alertness\n* Unstable ADHD\n* History of tympanic surgery for chronic otitis media\n* Legal impossibility","7 Years","15 Years",{"count":613,"type":23},150,"In clinical settings, hearing perception is typically assessed using audiometric tests administered in a controlled environment. To date, these tests are administered in silence or in the presence of noise from fixed sources at an arbitrarily predetermined signal-to-noise ratio. These assessment situations are not representative of the functional difficulties encountered by people with hearing loss or Auditory Processing Disorder in their daily lives. In real life, \"soundscapes\" are diverse. Hearing assessment and rehabilitation should include the child's everyday environments as well as their lifestyle habits.\n\nThe Immersion 360 System (Virtual reality system) was developed specifically to virtually reproduce complex everyday sound experiences with realistic noise types and sound presentation conditions, enabling the assessment of auditory perception under test conditions similar to those encountered in daily life. Some of the sound environments offered by this innovative system have been standardized for adults. No standards exist for children, and we have limited knowledge regarding the development of speech perception skills in noise during childhood and adolescence. It seems essential to measure the age-related development of speech perception in realistic sound environments in order to establish reference data for children and adolescents.\n\nThis work will, through functional assessments of the auditory system and linguistic tests (speech perception in noise), provide a better understanding of the functional development of the central auditory system for speech perception in noise. The results collected from normo-hearing individuals in the age groups of interest will provide a clinical baseline for comparison with patients of the same age.",[616,617,618],"Noise Exposure","Normal Hearing","Child","2026-06-23",{"date":485,"type":34},{"date":622,"type":23},"2026-07",{"date":624,"type":23},"2027-07",{"name":40,"class":41},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":19,"minAge":634,"maxAge":635,"enrollmentInfo":636,"targetDuration":4,"studyType":24,"phases":637,"briefSummary":639,"conditions":640,"keywords":641,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":72},"100621222","phase-1-allogeneic-adipose-tissue-derived-stem-cells-in-alzheimer-disease-100621222","NCT07367815","Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease","Allogeneic Intraveinous Injection of Adipose Tissue Derived-mesenchymal Stem Cells in Mild to Moderate Alzheimer Disease: a Phase I\u002FII Trial","A3D","Inclusion Criteria:\n\n* Patient between 50 and 85 years old\n* AD diagnosis according to NIA-AA 2011 criteria at a mild to moderate stage :\n\nMMSE score between 14 and 26 (include) positive AD amyloid biomarker\n\n* CDR (clinical dementia rating) score ≥ 1\n* Patient with no absolute contraindications for PET or MRI scans\n* Consent signed by the patient and study partner\n* presence of primary caregiver\n* Patient with social security coverage\n\nExclusion Criteria:\n\n* Brain disease (other than AD) that may cause dementia\n* Presence of concomitant pathologies not permitting participation in the study\n* Concurrent participation in other research that may influence the testing of the A3D study\n* Carrier of a pacemaker, valve prosthesis or other internal magnetic or electronic system, history of neurosurgery or aneurysm surgery, presence of metal fragments in the eyes, brain or marrow, claustrophobia\n* PET scan performed in the previous year (research context)\n* History of cancer diagnosed within the last 5 years\n* Presence of \\> 4 brain microbleeds, a single area of superficial siderosis, or evidence of previous macrohaemorrhage assessed by brain MRI scan\n* Regular use of corticosteroids or other steroidal anti-inflammatory drugs (e. g. prednisone)\n* Presence of an autoimmune disease (e. g. rheumatoid arthritis, systemic lupus erythematosus) with the exception of psoriasis\n* Pregnant or breastfeeding woman\n* Adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision For patients who will participate in the optional adipose puncture (only carried out in the Toulouse center): Antithrombotic treatment and xylocaine allergy are prohibited.","50 Years","85 Years",{"count":322,"type":23},[638,428],"PHASE1","A3D is a phase I\u002FII clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.",[431],[642,643,644,645,646],"Alzheimer disease,","phase I\u002FII,","safety,","mesenchymal stem cell,","adipose tissue","2026-06-18",{"date":619,"type":34},{"date":650,"type":34},"2026-05-07",{"date":652,"type":23},"2029-05-01",{"name":40,"class":41},{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":24,"phases":664,"briefSummary":665,"conditions":666,"keywords":670,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":72},"100629125","radiofrequency-ablation-versus-adrenalectomy-for-adenoma-in-patients-with-primary-aldosteronism-and-hypertension-100629125","NCT07470580","Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension","Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension: a Multicentre Prospective Randomized Study","ADERADHTA2","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Hypertension confirmed into the previous 9 months by ABPM 24h SBP\u002FDBP \\>130 and\u002For\u002F80 mmHg and\u002For diurnal SBP\u002FDBP \\> 135 and\u002For 85 mmHg and\u002For nocturnal SBP\u002FDBP \\>120 and\u002For 70 mmHg with or without antihypertensive treatment\n* Diagnosis of primary aldosteronism confirmed by hormonal assays no more than 1 year before inclusion\n* Presence of a unilateral adrenal nodule \\\u003C4 cm considered suggestive of a Conn's adenoma on an prior adrenal CT or MRI scan, no more than 1 year before inclusion\n* Adrenal venous sampling if age \\> 35 years (and according to investigator decision if age \\\u003C35 years) to look for a lateralization of secretion: cannulation was successful when adrenal\u002Fperipheral venous cortisol gradients\\>2 and lateralization was assessed by comparison of right and left adrenal venous aldosterone\u002Fcortisol ratios with a cut off value\\>4 ipsilateral to the nod side to define a positive lateralization of secretion (2) no more than 1 year before inclusion\n* nodule accessible to RFA according to the judgement of the interventional radiologist performing radiofrequency before randomisation\n* nodule accessible to surgery\n* patient willing to return for 6-month follow-up\n* adult patient able to read the information sheet and give consent to take part in the study\n* Patients affiliated to the French Health Insurance\n\nExclusion Criteria:\n\n* a negative lateralization of secretion on adrenal venous sampling\n* presence of bilateral adrenal tumours\n* contralateral or bilateral macronodular adrenal hyperplasia\n* no documented primary aldosteronism\n* Cushing's syndrome or pheochromocytoma\n* adrenal tumour \\> 4 cm\n* refusal to perform adrenal catheterisation if age \\> 35 years\n* double anti-platelet aggregation, coagulation disorders or patients treated with anticoagulant treatment that cannot be stopped\n* contraindication to anaesthesia\n* excessive proximity to sensitive adjacent organs\n* patient who has had a heart attack or stroke within the last 6 months\n* allergy to iodine\n* renal insufficiency defined as a clearance of \\\u003C30 ml\u002Fmin\n* refusal to undergo radiofrequency ablation or adrenal surgery\n* minors and patients under guardianship, curatorship or safeguard of justice\n* Inability to speak, read or write French fluently\n* patients who refuse follow-up\n* pregnant women or women wishing to become pregnant in the short term; breast-feeding\n* person taking part or having taken part in other interventional research in the previous 6 months\n* any other relevant exclusion criteria as determined by the investigator",{"count":663,"type":23},134,[26],"Primary aldosteronism (PA) is characterized by hypertension, frequent hypokalaemia, and an inappropriately high aldosterone-to-renin ratio (ARR). Aldosterone-producing adenoma (APA or Conn syndrome) is one of the main causes of primary aldosteronism. Laparoscopic (LA) total-adrenalectomy or adenoma selective is an option to normalize or at least improve blood pressure (BP) control, hypokalaemia, and normalize the ARR. However, the reported result of surgery is around 50% of clinical cure rate with an overall complication rate of 5 to 14% whereas hormonal success reached around 95%.\n\nMore recently, radiofrequency ablation (RFA) has been used for patients with primary aldosteronism and unilateral adenoma.\n\nInvestigator Team assume that treatment of unilateral PA by RFA could achieve similar efficacy to treatment by LA, with potentially less adverse events, and could be a more cost-efficient procedure.",[667,668,669],"Primary Aldosteronism Due to Conn Adenoma","Radiofrequency Ablation Treatment","Adrenalectomy",[671,672,673,674,675,676,677,678],"Primary aldosteronism","hypertension","hypokalaemia","aldosterone-to-renin ratio","Aldosterone-producing adenoma","Conn syndrome","radiofrequency ablation","adrenalectomy","2026-06-10",{"date":681,"type":34},"2026-06-11",{"date":683,"type":34},"2026-06-05",{"date":685,"type":23},"2030-06-01",{"name":40,"class":41},""]